Stock listing

Opus Genetics, Inc.

Selected listing: A2QG4Z · LSX · EUR · DE

Opus Genetics, Inc. (LS Exchange: A2QG4Z), Health Technology. Latest release Sep 9, 2026: Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase…

A2QG4Z:LSXEURDEUpdated October 2, 2026

Ticker: LS Exchange: A2QG4Z
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LS Exchange
Currency: EUR

Latest news from Opus Genetics, Inc.

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

September 9, 2026

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

September 2, 2026

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

August 6, 2026

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

August 3, 2026

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

July 9, 2026

All Opus Genetics, Inc. news →

Research Opus Genetics, Inc.

Opus Genetics, Inc. company profile

View the public company page for Opus Genetics, Inc. on 6ix.

Opus Genetics, Inc. news

Read company news and market updates connected to Opus Genetics, Inc..

Opus Genetics, Inc. investor events

Find investor webinars, events, and replay context for Opus Genetics, Inc..